SEC Filings

Form 424B3
EXICURE, INC. filed this Form 424B3 on 10/11/2018
Document Outline
Entire Document (2650.5 KB)
Subdocument 1 - 424B3 - 424B3
Page 1 - Filed pursuant to Rule 424(b)(3)
Page 2 - UNITED STATES
Page 3 - Item 8.01Other Events.
Page 4 - SIGNATURE
Page 5 - Exhibit 99.1
Page 6 - Our Strategy
Page 7 - Continue research and development in neurological applications.
Page 8 - Challenges in developing nucleic acid therapeutics
Page 9 - Our Proprietary Technology: Spherical Nucleic Acids
Page 10 - Examples of our proprietary SNA constructs
Page 11 - SNAs can be manufactured at commercial scale.
Page 12 - SNAs localize to endosomes of immune cells, engage multiple TLRs, and activate the immune system.
Page 13 - Our Research and Development Programs
Page 14 - Planned Phase 1b/2 development of AST-008
Page 15 - AST-008 in combination with checkpoint inhibitors
Page 16 - AST-008 in combination with a certain anti-PD-1 antibody in breast cancer mouse model resistant to a
Page 17 - The combination of AST-008 with an anti-PD-1 antibody shows improved tumor volume reduction and incr
Page 18 - Tumor growth and survival curves for combinations of AST-008 and an anti-PD-1 antibody in a lymphoma
Page 19 - AST-008 as a monotherapy for cancer.
Page 20 - Psoriasis market and current treatments
Page 21 - in vitroex vivoin vitroex vivo
Page 22 - AST-005topically applied SNAs for psoriasis
Page 23 - Nusinersen in SNA format prolonged survival compared to linear nusinersen in 7 SMA mice. The 20 g tr
Page 24 - Oral administration of anti-TNF SNAs improve clinical scoring, left panel, and pathology results, ri
Page 25 - The distribution of SNAs in rabbit eyes when administered as topical drops demonstrates that SNAs pe
Page 26 - Nebulized SNAs can induce an immune response in lung tissue, BAL, and serum.
Page 27 - Patent Rights
Page 28 - Trade Secret and Other Protection
Page 29 - in vitro
Page 30 - Manufacturing and Supply
Page 31 - Competition
Page 32 - Government Regulation and Product Approval
Page 33 - in vitro
Page 34 - N/A
Page 35 - Companion Diagnostics
Page 36 - N/A
Page 37 - N/A
Page 38 - N/A
Page 39 - New Legislation and Regulations
Page 40 - Healthcare Reform
Page 41 - Third-Party Payor Coverage and Reimbursement
Page 42 - N/A
Page 43 - Other Healthcare Laws and Regulations
Page 44 - N/A
Page 45 - Environment
Page 46 - Employees
Page 47 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 48 - N/A

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet